11,000 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Bought by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft purchased a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 11,000 shares of the company’s stock, valued at approximately $192,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Aigen Investment Management LP acquired a new stake in Travere Therapeutics during the 3rd quarter valued at approximately $170,000. Oppenheimer & Co. Inc. acquired a new position in Travere Therapeutics in the third quarter valued at $673,000. Millennium Management LLC grew its stake in Travere Therapeutics by 33.9% during the second quarter. Millennium Management LLC now owns 2,949,335 shares of the company’s stock worth $24,244,000 after purchasing an additional 747,406 shares during the period. FMR LLC grew its position in shares of Travere Therapeutics by 27.5% during the 3rd quarter. FMR LLC now owns 147,416 shares of the company’s stock worth $2,062,000 after buying an additional 31,772 shares during the period. Finally, Two Sigma Advisers LP lifted its position in shares of Travere Therapeutics by 30.2% during the 3rd quarter. Two Sigma Advisers LP now owns 720,400 shares of the company’s stock valued at $10,078,000 after acquiring an additional 167,100 shares during the period.

Insiders Place Their Bets

In other news, CAO Sandra Calvin sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $17.22, for a total value of $258,300.00. Following the completion of the transaction, the chief accounting officer now directly owns 54,927 shares in the company, valued at approximately $945,842.94. This trade represents a 21.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Peter Heerma sold 1,584 shares of the company’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $18.94, for a total transaction of $30,000.96. Following the sale, the insider now directly owns 106,374 shares in the company, valued at $2,014,723.56. This trade represents a 1.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 62,143 shares of company stock worth $1,167,512 in the last quarter. 3.75% of the stock is owned by company insiders.

Travere Therapeutics Stock Down 2.8 %

TVTX opened at $20.46 on Friday. Travere Therapeutics, Inc. has a 12 month low of $5.12 and a 12 month high of $21.56. The company has a market cap of $1.60 billion, a PE ratio of -4.50 and a beta of 0.70. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The company has a 50 day moving average of $18.61 and a 200 day moving average of $15.25.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.01. The firm had revenue of $62.90 million during the quarter, compared to analyst estimates of $60.87 million. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. The business’s revenue for the quarter was up 69.6% on a year-over-year basis. During the same period last year, the company earned ($1.17) earnings per share. On average, sell-side analysts expect that Travere Therapeutics, Inc. will post -3.92 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Wedbush boosted their price objective on Travere Therapeutics from $17.00 to $25.00 and gave the company an “outperform” rating in a report on Wednesday, October 9th. Barclays upped their price objective on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Piper Sandler boosted their price objective on Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a research report on Thursday, November 14th. Guggenheim lifted their target price on Travere Therapeutics from $23.00 to $41.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Finally, HC Wainwright increased their price target on shares of Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a research report on Wednesday, January 15th. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, Travere Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.